Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy

Inclusion Criteria

• •Patient with CIPN manifested by painful symptoms such as numbness and / or tingling and / or burning pain in fingers / hands and toes / feet with a typical distribution in "gloves and socks" beginning after neurotoxic chemotherapy
• •Painful CIPN as expressed by the BPI-SF (average pain) as ≥ 4/10
• •CIPN persisting at least 1 month after completion of chemotherapy with taxanes and/or platinum salts and sensory CIPN grade ≥ 2 according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE v.5.0) grading scale
• •Stable doses in the 4 weeks before screening, of concomitant neuropathic pain medication (antiepileptic drugs)
• •Healthy and non-irritated skin on the areas to be treated
• •Absence of neurotoxic chemotherapy planned during the next 6 months after inclusion
• •Patient affiliated to a social security scheme
• •\> 18 years old
• •Signed written informed consent form